Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ICML 2023 and Diffuse Large B Cell Lymphoma View overview page

1:09
Loncastuximab tesirine: long-term survival data from LOTIS-2 & insights into the LOTIS-7 trial
Juan Alderuccio • 15 Jun 2023
0:49
SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHL
Jason Westin • 16 Jun 2023
1:16
Insights into the Phase II Smart Stop study
Jason Westin • 16 Jun 2023
1:15
Primary overall survival analysis of the ZUMA-7 trial
Jason Westin • 16 Jun 2023
1:09
The changing role of alloSCT in DLBCL in the era of novel agents
Matthew Ulrickson • 15 Jun 2023
1:09
Optimizing CAR-T outcomes in DLBCL: possible combination strategies & sequencing of agents
Matthew Ulrickson • 15 Jun 2023
1:51
Efficacy of odronextamab in R/R DLBCL & determining the optimal sequencing of immune therapies
Michelle Poon • 19 Jun 2023
1:15
Promising agents emerging for Richter’s transformation
Chan Yoon Cheah • 16 Jun 2023
3:09
The role of epcoritamab in third-line or later LBCL
Chan Yoon Cheah • 16 Jun 2023
1:15
The benefits of glofitamab in R/R DLBCL post-CAR-T therapy
Graham Collins • 16 Jun 2023
7:13
Efficacy and safety of glofitamab for patients with Richter’s transformation
Carmelo Carlo-Stella • 15 Jun 2023
1:30
The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins • 16 Jun 2023
2:47
CC-99282 ± rituximab for R/R NHL: Phase I/II trial interim analysis
Jean-Marie Michot • 16 Jun 2023
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023
1:21
Improving MRD assessment and response criteria in DLBCL: insights into PhasED-Seq
Mark Roschewski • 16 Jun 2023
2:49
Tafasitamab-lenalidomide in R/R DLBCL: clinical trial results and real-world data
Gabriel Brisou • 14 Jun 2023
The content of VJHemOnc is intended for healthcare professionals